Genmab Acquires Rights for 16 Cancer Targets

20-May-2005

Genmab A/S announced that it has acquired rights to 16 potential targets to treat non-steroid dependent cancers of epithelial cell origin, such as gastrointestinal cancers, including colon cancer, from the insolvency administrator of Europroteome, AG, a privately owned German company currently in insolvency proceedings.

Genmab purchased all of Europroteome's rights, including patent applications and know how, and does not owe anything further to the insolvency estate. There are no milestone or royalty obligations.

Genmab has started generating human antibodies to a unique target highly expressed on colon carcinomas.

"These rights give Genmab access to numerous cancer targets, including ones for colon cancer, providing the opportunity to further build our pre-clinical pipeline," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

The acquisition of these rights does not influence Genmab's financial guidance for 2005.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous